Valuation : Rigel Pharmaceuticals, Inc.

Market Cap 909M 782M 735M 671M 1.26B 85.98B 1.26B 8.72B 3.37B 44.03B 3.41B 3.34B 140B P/E 2026 *
15.5x
P/E 2027 * 12.5x
Enterprise Value 909M 782M 735M 671M 1.26B 85.98B 1.26B 8.72B 3.37B 44.03B 3.41B 3.34B 140B EV / Sales 2026 *
2.97x
EV / Sales 2027 * 2.44x
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day+0.35%
1 week+5.39%
Current month+5.39%
1 month+21.16%
3 months+62.61%
6 months+68.58%
Current year+13.64%
1 week 47.73
Extreme 47.73
49.9
1 month 39.9
Extreme 39.9
49.9
Current year 24.95
Extreme 24.95
49.9
1 year 24.95
Extreme 24.95
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 21/11/2014
Director of Finance/CFO 63 29/05/2018
Compliance Officer 58 01/12/2022
Director TitleAgeSince
Director/Board Member 71 01/03/1997
Director/Board Member 65 21/11/2014
Chairman 67 01/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Exercice

Chief Financial Officer

9,200 0.0493%
01/09/26 Tax

Compliance Officer

-877 0.0047%
01/09/26 Tax

Chief Executive Officer

-2,424 0.0130%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%+5.39%+17.73%+342.45% 909M
-0.88%-0.64%+58.05%+100.51% 1,024B
-1.15%+3.53%+54.25%+71.99% 663B
-1.44%+0.02%+20.65%+72.22% 453B
-0.25%+1.21%+30.21%+37.01% 349B
-9.01%-13.23%+11.06%+28.96% 295B
-0.76%-0.07%-0.13%+10.22% 253B
-1.55%+1.71%+54.15%+71.87% 236B
-0.94%+0.71%-14.69%-56.32% 206B
-0.15%+3.18%+31.24%+104.21% 187B
Average -1.43%+1.52%+26.25%+78.31% 366.82B
Weighted average by Cap. -1.35%+0.52%+36.59%+63.44%

Financials

2026 *2027 *
Net sales 306M 263M 247M 226M 422M 28.91B 424M 2.93B 1.13B 14.81B 1.15B 1.12B 47.16B 373M 321M 302M 275M 515M 35.26B 517M 3.58B 1.38B 18.06B 1.4B 1.37B 57.52B
Net income 61.66M 53.03M 49.87M 45.53M 85.14M 5.83B 85.42M 591M 229M 2.99B 232M 226M 9.51B 81.45M 70.04M 65.88M 60.14M 112M 7.7B 113M 781M 302M 3.94B 306M 299M 12.56B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
04/09/26 $48.67 +0.35% 104,968
03/09/26 $48.50 -1.86% 190,389
02/09/26 $49.42 +4.04% 184,699
01/09/26 $47.50 +2.86% 205,505
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
48.67USD
Average target price
63.00USD
Spread / Average Target
+29.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!